$ZLDPF

Zealand Pharma (ZEAL.CO) reported positive Phase 1 trial results for ZP9830, an investigational Kv1.3 ion channel blocker. The trial showed favorable tolerability with no serious adverse events. The company plans further trials in plaque psoriasis and another autoimmune disease. ZEAL.CO shares are trading at DKK 221.50, down 2.12%.

Zealand Pharma (ZEAL) partnered with Generate Biomedicines to develop AI-designed protein therapeutics for obesity and metabolic diseases. Generate receives $30M upfront, up to $35M in early milestones, and potential $1.2B in total milestones plus royalties. The collaboration expands Zealand's focus into AI-designed proteins.

Zealand Pharma reported positive Phase 2 results for petrelintide, showing 9.2% mean weight loss vs 2.0% placebo and HbA1c reductions of 0.61%-0.88%. No unexpected safety issues were noted. The company is moving into Phase 3 trials with Roche.

Zealand Pharma A/S (ZEAL) completed a share buyback program, repurchasing 4.4 million shares for DKK 1.3 billion at an average price of DKK 294.88. The company now holds 5.3 million treasury shares, representing 7.37% of its share capital, according to the company.

Zealand Pharma (ZEAL) opened a new research hub in Cambridge, Massachusetts, expanding its metabolic health research capabilities. The company aims to become a leader in obesity and metabolic health, with the new hub focusing on hybrid modalities and advanced modeling techniques. Zealand Pharma is actively hiring and expects continued growth at the site.

Zealand Pharma's stock fell 11.7% after its partner Boehringer Ingelheim released Phase III trial results for survodutide. The drug met its primary endpoints, but 18% of patients discontinued due to gastrointestinal side effects. Investors are concerned about the drug's differentiation in the competitive obesity market, impacting Zealand's future revenues.

Zealand Pharma's shares dropped 12.5% after a Phase III trial of its obesity drug survodutide showed significant weight loss in type 2 diabetes patients, but 18% discontinued due to gastrointestinal side effects. The trial met its main goals, with patients losing up to 13.1% body weight. The drug is licensed to Boehringer Ingelheim, which is responsible for its development and commercialization.

Zealand Pharma reported that Boehringer Ingelheim's survodutide achieved co-primary endpoints in its Phase III trial, with participants experiencing up to 13.1% weight loss compared to 3.1% for placebo over 76 weeks. The drug also improved glycemic control in adults with obesity or type 2 diabetes, according to the company.

Zealand Pharma (ZEAL.CO) announced a positive EU opinion for Zeydovio (glepaglutide) in treating short bowel syndrome, based on Phase 3 trial data. The CHMP recommendation, supported by significant trial results, awaits European Commission approval. The company is also advancing a U.S. trial for potential FDA submission.

Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.